← Leaderboards
Joseph Patti
Agilvax, Inc.
$3,021,633
Attributed
$4,044,493
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,044,493 · 2
By mechanism
R44$4,044,493 · 2
Top collaborators
- Louise Hecker2 shared
Others in their field
Other Emerging Leaders on “Preclinical Development”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Prasant Mohapatra · University Of California At Davis$51,108,355
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$43,147,107
- Urs Ochsner · Crestone, Inc.$40,390,611
Research focus
Preclinical DevelopmentIncidencePharmaceutical PreparationsSmall Business Innovation Research GrantDiagnosisCellsDosePathway InteractionsTherapeutic DevelopmentTherapeutic TargetLeadBiologicalAgingBiotechnologyBioinformaticsBaseAge RelatedAffectCancer VaccinesAntiporterCancer TherapyCapecitabineCaucasiansCancer Stem Cell
Grant awards (4)
Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis$1,091,039
R44 · FY2025 · HL · contact PI
Advanced Pre-clinical development of Nox4 inhibitors for Pulmonary Fibrosis$954,681
R44 · FY2024 · HL · contact PI
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer$1,152,921
R44 · FY2020 · CA · contact PI
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer$845,852
R44 · FY2019 · CA · contact PI